retatrutide glucagon receptor vs. Ozempic GLP-3 (R) - Triple GIP

Steady-state concentrations are achieved after approximately four to five weeks of once-weekly dosing

However, liraglutide treatment failed to show significant improvement of the UACR and eGFR trajectory in comparison to placebo ( The Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) study assessed the CV outcome of liraglutide (1.8 mg) in comparison to placebo (Marso et al., 2016b)

Advertorial Disclosure: This content is promotional in nature and is intended for consumer education regarding a commercially available telehealth service

Weight loss followed a predictable progression throughout the trial period